AUVEN THERAPEUTICS Trademark

Trademark Overview

On Monday, December 10, 2012, a trademark application was filed for AUVEN THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the AUVEN THERAPEUTICS trademark a serial number of 85798412. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, July 26, 2024. This trademark is owned by AUVEN THERAPEUTICS MANAGEMENT. The AUVEN THERAPEUTICS trademark is filed in the Insurance & Financial Services and Computer & Software Services & Scientific Services categories with the following description:

Management of private equity funds; Private equity fund investment services

Conducting early evaluations in the field of new pharmaceuticals; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; Development of pharmaceutical preparations and medicines; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical research and development
auven therapeutics

General Information

Serial Number85798412
Word MarkAUVEN THERAPEUTICS
Filing DateMonday, December 10, 2012
Status710 - CANCELLED - SECTION 8
Status DateFriday, July 26, 2024
Registration Number4467681
Registration DateTuesday, January 14, 2014
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 28, 2013

Trademark Statements

Goods and ServicesManagement of private equity funds; Private equity fund investment services
NOT AVAILABLE"THERAPEUTICS"
Goods and ServicesConducting early evaluations in the field of new pharmaceuticals; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; Development of pharmaceutical preparations and medicines; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical research and development

Classification Information

International Class036 - Insurance; financial affairs; monetary affairs; real estate affairs.
US Class Codes100, 101, 102
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, July 26, 2024
Primary Code036
First Use Anywhere DateMonday, March 11, 2013
First Use In Commerce DateMonday, March 11, 2013
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, July 26, 2024
Primary Code042
First Use Anywhere DateMonday, March 11, 2013
First Use In Commerce DateMonday, March 11, 2013

Trademark Owner History

Party NameAUVEN THERAPEUTICS MANAGEMENT
Party Type31 - New Owner After Registration
Legal Entity Type20 - NOT AVAILABLE
AddressST. THOMAS, VI 00802
Party NameNOT AVAILABLE
Party Type30 - Original Registrant
Legal Entity Type01 - Individual
AddressSt Thoams, VI 00802
Party NameNOT AVAILABLE
Party Type20 - Owner at Publication
Legal Entity Type01 - Individual
AddressSt Thoams, VI 00802
Party NameNOT AVAILABLE
Party Type10 - Original Applicant
Legal Entity Type01 - Individual
AddressSt Thoams, VI 00802

Trademark Events

Event DateEvent Description
Tuesday, March 26, 2013ASSIGNED TO EXAMINER
Thursday, December 13, 2012NEW APPLICATION ENTERED
Thursday, December 20, 2012NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, March 28, 2013EXAMINER'S AMENDMENT ENTERED
Thursday, March 28, 2013EXAMINERS AMENDMENT -WRITTEN
Thursday, March 28, 2013EXAMINERS AMENDMENT E-MAILED
Thursday, March 28, 2013NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, May 28, 2013OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Thursday, March 28, 2013APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, April 19, 2013ASSIGNED TO LIE
Friday, April 19, 2013LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, May 8, 2013NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 28, 2013PUBLISHED FOR OPPOSITION
Monday, September 16, 2013TEAS STATEMENT OF USE RECEIVED
Tuesday, November 19, 2013ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, July 23, 2013NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, September 16, 2013USE AMENDMENT FILED
Wednesday, October 23, 2013STATEMENT OF USE PROCESSING COMPLETE
Friday, October 11, 2013CASE ASSIGNED TO INTENT TO USE PARALEGAL
Sunday, November 3, 2013SU - NON-FINAL ACTION - WRITTEN
Sunday, November 3, 2013NON-FINAL ACTION E-MAILED
Sunday, November 3, 2013NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, November 19, 2013TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, January 14, 2014REGISTERED-PRINCIPAL REGISTER
Monday, January 14, 2019COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Tuesday, November 19, 2013TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, November 21, 2013APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, November 21, 2013CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, November 21, 2013TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, December 6, 2013ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, December 11, 2013LAW OFFICE REGISTRATION REVIEW COMPLETED
Thursday, December 12, 2013NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Wednesday, February 26, 2014AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Saturday, January 14, 2023COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Friday, July 26, 2024CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9
Saturday, December 21, 2019NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Tuesday, November 12, 2019TEAS SECTION 8 & 15 RECEIVED
Saturday, December 21, 2019CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Saturday, December 21, 2019REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.

Related Keywords

therapeutics auven pharmaceutical development services research consulting fields biotechnology equity private pharmacogenetics